Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
35.5M
-
Shares change
-
-892K
-
Total reported value, excl. options
-
$287M
-
Value change
-
-$17M
-
Put/Call ratio
-
0.01
-
Number of buys
-
51
-
Number of sells
-
-36
-
Price
-
$8.09
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2022
108 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q2 2022.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.5M shares
of 53.1M outstanding shares and own 66.83% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), Vivo Capital, LLC (4.22M shares), FMR LLC (3.99M shares), Logos Global Management LP (3.14M shares), ORBIMED ADVISORS LLC (2.19M shares), BlackRock Inc. (1.66M shares), VANGUARD GROUP INC (1.32M shares), WELLINGTON MANAGEMENT GROUP LLP (1.13M shares), Redmile Group, LLC (767K shares), and Cormorant Asset Management, LP (712K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.